Spots Global Cancer Trial Database for imaging biomarker analysis
Every month we try and update this database with for imaging biomarker analysis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01098344 | Pancreatic Canc... | Notch signaling... gemcitabine hyd... imaging biomark... laboratory biom... pharmacological... | 18 Years - | Cancer Research UK | |
Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32 | NCT01666171 | Breast Cancer | metformin hydro... clinical observ... diagnostic labo... imaging biomark... medical chart r... digital mammogr... | 18 Years - 74 Years | National Cancer Institute (NCI) | |
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma | NCT00756106 | Brain and Centr... | temozolomide Imaging biomark... Photon Radiatio... | 18 Years - | Massachusetts General Hospital | |
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | NCT00665457 | Breast Cancer | filgrastim capecitabine celecoxib cyclophosphamid... docetaxel doxorubicin hyd... gene expression... polymorphism an... protein express... reverse transcr... imaging biomark... immunohistochem... laboratory biom... pharmacogenomic... dynamic contras... needle biopsy neoadjuvant the... radiomammograph... ultrasound imag... | 19 Years - 120 Years | University of Nebraska | |
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | NCT00665457 | Breast Cancer | filgrastim capecitabine celecoxib cyclophosphamid... docetaxel doxorubicin hyd... gene expression... polymorphism an... protein express... reverse transcr... imaging biomark... immunohistochem... laboratory biom... pharmacogenomic... dynamic contras... needle biopsy neoadjuvant the... radiomammograph... ultrasound imag... | 19 Years - 120 Years | University of Nebraska | |
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma | NCT00756106 | Brain and Centr... | temozolomide Imaging biomark... Photon Radiatio... | 18 Years - | Massachusetts General Hospital | |
CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery | NCT00635245 | Breast Cancer | figitumumab imaging biomark... laboratory biom... pharmacological... conventional su... magnetic resona... neoadjuvant the... | 18 Years - | Pfizer | |
Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance | NCT00796874 | Prostate Cancer | active surveill... imaging biomark... biopsy dynamic contras... magnetic resona... magnetic resona... | 18 Years - | Roswell Park Cancer Institute | |
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder | NCT01222676 | Bladder Cancer | cisplatin gemcitabine hyd... sorafenib tosyl... imaging biomark... laboratory biom... computed tomogr... neoadjuvant the... fludeoxyglucose... | 18 Years - | National Cancer Institute (NCI) | |
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01098344 | Pancreatic Canc... | Notch signaling... gemcitabine hyd... imaging biomark... laboratory biom... pharmacological... | 18 Years - | Cancer Research UK |